Cancer immunotherapy and biotech innovation by PDS Biotechnology

  • Elena Nikulina
  • Yesterday
Third quarter results released by PDS Biotechnology
PDS Biotechnology has published its financial results for the third quarter. The announcement provides investors and stakeholders with the latest overview of the company’s fiscal position and ...
  • Ksenia Gerey
  • 20.10.2026
PDS Biotechnology appoints three new pharma executives to board
PDS Biotechnology has announced the appointments of John Dawson, Deborah Ramsdell, and Bruce Wendel to its Board of Directors. The three executives bring extensive experience in the pharmaceutical ...
  • Yaroslav Dmytrenko
  • 06.10.2026
PDS Biotechnology to unveil new PDS0301 clinical outcomes at upcoming expert event
PDS Biotechnology announced it will host a virtual key opinion leader (KOL) event on October 15 at 8 a.m. ET. The event will feature Dr. Jonathan M. Hernandez of the U.S. National Cancer ...
  • Yulia Slavina
  • 22.09.2026
PDS Biotechnology publishes Phase 2 immunotherapy results and shifts focus to PDS0301 in mCRC
PDS Biotechnology announced that results from a Phase 2 trial of its HPV16-targeted immunotherapy, PDS0101, combined with pembrolizumab, have been published in JAMA Oncology. The company stated ...
  • Yulia Slavina
  • 13.08.2026
Revenue steady but operating expenses rise for PDS Biotechnology in latest quarterly report
PDS Biotechnology has announced its financial results for the second quarter of 2026. The report indicates a wider operating loss for the period, reflecting increased expenses as the company ...